Pharmacist counseling in a cohort of women with HIV and women at risk for HIV

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 457-463

  Cocohoba, Jennifer M ^a   Althoff, Keri N ^b   Cohen, Mardge ^c   Hu, Haihong ^d   Cunningham, Chinazo O ^e   Sharma, Anjali ^f   Greenblatt, Ruth M ^a,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral therapy; Community pharmacy; Human immunodeficiency virus; Pharmacy practice; Women's health

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; COUNSELING; CROSS-SECTIONAL STUDY; DEPRESSION; EDUCATIONAL STATUS; FEMALE; HEALTH STATUS; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACIST; PROSPECTIVE STUDY; SELF REPORT; TREATMENT DURATION; UNIVARIATE ANALYSIS; VIRUS LOAD;

EID: 84881386681     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S30797     Document Type: Article

References (37)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860.
2. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al; HIV Outpatient Study Investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138(8):620-626.
3. Sabate E. Adherence to long-term therapies: evidence for action, 2003. Available from: http://whqlibdoc.who.int/publications/2003/9241545992.pdf. Accessed June 16, 2008.
4. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28(5):445-449.
5. Johnson MO, Charlebois E, Morin SF, et al. Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage. 2005;29(2):193-205.
6. Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behav. 2003;7(1):61-72.
7. Barfod TS, Hecht FM, Rubow C, Gerstoft J. Physicians' communication with patients about adherence to HIV medication in San Francisco and Copenhagen: a qualitative study using grounded theory. BMC Health Serv Res. 2006;6:154.
8. Laws MB, Beach MC, Lee Y, et al. Provider-patient adherence dialogue in HIV care: results of a multisite study. AIDS Behav. January 31, 2012. [Epub ahead of print.]
9. Wilson IB, Laws MB, Safren SA, et al. Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIV. J Acquir Immune Defic Syndr. 2010;53(3):338-347.
10. Barnett MJ, Frank J, Wehring H, et al. Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years. J Manag Care Pharm. 2009;15(1):18-31.
11. D'Antonio N. Including motivational interviewing skills in the PharmD curriculum. Am J Pharm Educ. 2010;74(8):152d.
12. Ahmad A, Hugtenburg J, Welschen LM, Dekker JM, Nijpels G. Effect of medication review and cognitive behaviour treatment by community pharmacists of patients discharged from the hospital on drug related problems and compliance: design of a randomized controlled trial. BMC Public Health. 2010;10:133.
13. Rosenquist A, Best BM, Miller TA, Gilmer TP, Hirsch JD. Medication therapy management services in community pharmacy: a pilot programme in HIV specialty pharmacies. J Eval Clin Pract. 2010;16(6):1142-1146.
14. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12(9):1013-1019.
15. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9(2):117-125.
16. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38(1):96-103.
17. Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011;8(4):277-287.
18. Sohler NL, Li X, Cunningham CO. Gender disparities in HIV health care utilization among the severely disadvantaged: can we determine the reasons? AIDS Patient Care STDS. 2009;23(9):775-783.
19. Sayles JN, Wong MD, Cunningham WE. The inability to take medications openly at home: does it help explain gender disparities in HAART use? J Womens Health (Larchmt). 2006;15(2):173-181.
20. Bozek PS, Perdue BE, Bar-Din M, Weidle PJ. Effect of pharmacist interventions on medication use and cost in hospitalized patients with or without HIV infection. Am J Health Syst Pharm. 1998;55(11):1151-1155.
21. Castillo E, Palepu A, Beardsell A, et al. Outpatient pharmacy care and HIV viral load response among patients on HAART. AIDS Care. 2004;16(4):446-457.
22. de Maat MM, de Boer A, Koks CH, et al. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV care. J Clin Pharm Ther. 2004;29(2):121-130.
23. Frick P, Tapia K, Grant P, Novotny M, Kerzee J. The effect of a multidisciplinary program on HAART adherence. AIDS Patient Care STDS. 2006;20(7):511-524.
24. Horberg MA, Hurley LB, Silverberg MJ, Kinsman CJ, Quesenberry CP. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(5):531-539.
25. Krummenacher I, Cavassini M, Bugnon O, Schneider MP. An interdisciplinary HIV-adherence program combining motivational interviewing and electronic antiretroviral drug monitoring. AIDS Care. 2011;23(5):550-561.
26. Krummenacher I, Cavassini M, Bugnon O, Spirig R, Schneider MP; Swiss HIV Cohort Study. Antiretroviral adherence program in HIV patients: a feasibility study in the Swiss HIV Cohort Study. Pharm World Sci. 2010;32(6):776-786.
27. Levy RW, Rayner CR, Fairley CK, et al. Multidisciplinary HIV adherence intervention: a randomized study. AIDS Patient Care STDS. 2004;18(12):728-735.
28. Ma A, Chen DM, Chau FM, Saberi P. Improving adherence and clinical outcomes through an HIV pharmacist's interventions. AIDS Care. 2010;22(10):1189-1194.
29. McPherson-Baker S, Malow RM, Penedo F, Jones DL, Schneiderman N, Klimas NG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care. 2000;12(4):399-404.
30. Ostrop NJ, Gill MJ. Antiretroviral medication adherence and persistence with respect to adherence tool usage. AIDS Patient Care STDS. 2000;14(7):351-358.
31. Rathbun RC, Farmer KC, Stephens JR, Lockhart SM. Impact of an adherence clinic on behavioral outcomes and virologic response in the treatment of HIV infection: A prospective, randomized, controlled pilot study. Clin Ther. 2005;27(2):199-209.
32. Smith SR, Rublein JC, Marcus C, Brock TP, Chesney MA. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns. 2003;50(2):187-199.
33. Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best BM. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm. 2011;17(3):213-223.
34. Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries. J Manag Care Pharm. 2009;15(1):32-41.
35. Smith SR, Golin CE, Reif S. Influence of time stress and other variables on counseling by pharmacists about antiretroviral medications. Am J Health Syst Pharm. 2004;61(11):1120-1129.
36. Horberg MA, Bartemeier Hurley L, James Towner W, et al. Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. March 19, 2012. [Epub ahead of print.]
37. March K, Mak M, Louie SG. Effects of pharmacists' interventions on patient outcomes in an HIV primary care clinic. Am J Health Syst Pharm. 2007;64(24):2574-2578.